N
Navigo Proteins
Discovers and develops novel scaffold proteins-based affinity ligands for commercial biologics GMP purification or as biopharmaceutical drugs/binders.
About Navigo Proteins
Navigo Proteins GmbH is a specialized biotechnology company focused on the development of engineered protein ligands and affinity solutions for the biopharmaceutical and life sciences industries. Formerly known as Scil Proteins GmbH, the company operates in the protein engineering market, serving customers that include biopharma companies, diagnostics developers, and research organizations.
Navigo Proteins’ business model centers on the development, production, and commercialization of proprietary scaffold-based proteins, including its Affilin® technology, which is used for applications such as affinity chromatography, bioprocessing, diagnostics, and targeted therapeutic development. The company supports clients across the biopharmaceutical value chain, from early research through manufacturing optimization.
Revenue is generated through a combination of product sales (e.g. affinity ligands), custom development projects, strategic collaborations, and licensing agreements. Navigo Proteins differentiates itself through deep expertise in protein design, molecular engineering, and scalable production, enabling highly specific and robust solutions for complex biological targets.
Headquartered in Germany, Navigo Proteins continues to build on decades of experience in protein engineering, positioning itself as a technology-driven partner for next-generation bioprocessing and biotherapeutic innovation.
Source: Dealroom company dataAt a glance
- Status
- Acquired
- Founded
- 1999
- Headquarters
- Halle (Saale), Germany
- Employees
- 58
- Open positions
- 1
- Dealroom signal
- 81.0/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Oncology, Health Diagnostics, Biotech and Pharma, Radioisotope Therapeutics, Radiopharmaceuticals, proteomics, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b, b2c
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITION✓Exit | Jan 2017 | $0 | — | UV-Cap | ↗ |
| LATE VC✓Equity / VC | Feb 2011 | $26M | $106M | BioNet Holding | — |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for Navigo Proteins is 300 monthly website visits, down 23.1% over the last three months. Navigo Proteins's team grew 87.1% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later1 investor entered at this stage
- BHBioNet Holding
Other known investors1 additional known investor
UV-Cap
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Navigo Proteins on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Navigo Proteins’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.